Glazman-Kuśnierczyk, Halina ; Pajtasz-Piasecka, Elżbieta ; Radzikowski, Czesław
Committee on Biotechnology PAS ; Institute of Bioorganic Chemistry PAS
terleukin 2 cDNA (X63-mIL-2) were used as the slow-release system of IL-2 for immunotherapyand chemoimmunotherapy in mice challenged with subcutaneous injections of different non-related tumors (MCA induced fibrosarcomas BFSl and F-69-3, colon carcinoma C38). The combination of one dose of the cytostatic agent (bromoanalog of ifosfamide) administration withsubsequent peritumoral injections of the cytokine-producing cells was observed to be more efficient in the tumor growth inhibition as compared with the cytostatic alone.
Biotechnologia, vol.35, 4 (1996)-.
0860-7796 ; oai:rcin.org.pl:146555 ; IChB B-31
Library of Institute of Bioorganic Chemistry PAS
Creative Commons Attribution BY-SA 4.0 license
Institute of Bioorganic Chemistry of the Polish Academy of Science
Institute of Bioorganic Chemistry of the Polish Academy of Science
Nov 9, 2020
Nov 9, 2020
45
https://rcin.org.pl./publication/182221
Borkowska, Bożenna
Ziółkowski, Piotr Babula- Skowrońska, Danuta Kaczmarek, Małgorzata Cieśla, Agata Sadowski, Jan